Januvia licenced for triple therapy

Januvia (sitagliptin) has had its licence extended to include use in triple therapy alongside metformin and a sulfonylurea or a glitazone in type II diabetes inadequately controlled by dual therapy.

The dosage of metformin and glitazone should be maintained and the Januvia dose administered concomitantly.

If it is used in combination with a sulfonylurea, the dose of sulfonylurea may need to be lowered to reduce the risk of hypoglycaemia. The recommended dose of Januvia is 100mg once daily.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...